Expresión de la enzima APE1 en biopsias de pacientes con cáncer de mama tratadas con monoquimioterapia neoadyuvante con antraciclinas

GAUNA G.; NADIN S.B.; DAGUERRE P.; LEUZZI M.; GAGO F.E.; IBARRA J.; VARGAS ROIG L.M.

Corrientes

Congreso; XXII Congreso Científico Argentino de Estudiantes de Medicina; 2011

APE1 expression in biopsies from breast cancer patients treated with anthracyclines neoadjuvant monochemotherapy. Doxorubicin (DOX) produces reactive oxygen species which damage DNA. This damage may be repaired by the Base Excision Repair system (BER). APE1 is a key enzyme in BER. Objectives: 1) to determine the APE1 expression before and after chemotherapy with DOX or epirubicin (EPI) and 2) to correlate APE1 with drug response and patient survival. Thirty-three patients received 75 mg/m2 of DOX or 120 mg/m2 of EPI, during 4 cycles  before surgery, and 6 cycles with CMF after surgery. Nuclear expression of APE1 (evaluated by immunohistochemistry) increased after drug administration (p = 0,03). No correlation was found between nuclear/cytoplasmic APE1 expression with clinical/pathological response.